Table 2.
Hazard ratios for cohort, HCV subgroup and DAA subgroup.
| Total | HCV | DAA | |
|---|---|---|---|
| Sex - Male/Female | 1.25 (0.99–1.49, p = 0.0592) | 1.28 (0.89–1.89, p = 0.1924) | 1.30 (0.39–5.25, p = 0.6799 |
| Liver Factors | |||
| MELD | 1.03 (1.00–1.06, p = 0.0168) | 1.05 (1.00–1.11, p = 0.0468) | 1.21 (1.02–1.44, p = 0.0326) |
| Tumor Size | 1.06 (1.02–1.09, p < 0.0007) | 1.01 (0.95–1.06, p = 0.08082) | 0.75 (0.49–1.06, p = 0.1044) |
| Bilobar/Unilobar | 1.32 (1.03–1.69, p = 0.026) | 1.62 (1.14–2.30, p = 0.0072) | 1.38 (0.36–5.51, p = 0.6354) |
| Multiple Tumors - yes/no | 1.03 (0.80–1.32, p = 0.816) | 1.27 (0.88–1.83, p = 0.1986) | 1.01 (0.41–2.99, p = 0.9831) |
| AJCC | |||
| 4/1 | 2.77 (1.86–4.08, p < 0.0001) | 1.59 (0.79–3.09, p = 0.19) | |
| 4/2 | 2.06 (1.40–3.01, p = 0.0003) | 1.32 (0.67–2.53, p = 0.4209) | |
| 4/3 | 1.21 (0.86–1.68, p = 0.2704) | 0.75 (0.42–1.31, p = 0.3186) | |
| 3/1 | 2.29 (1.69–3.09, p < 0.0001) | 2.11 (1.25–5.54, p < 0.0051) | 1.81 (0.08–13.48, p = 0.6350) |
| 3/2 | 1.70 (1.26–2.30, p = 0.0005) | 1.76 (1.05–2.92, p = 0.0328) | 2.28 (0.10–19.85, p = 0.5336) |
| 2/1 | 1.34 (1.03–1.75, p = 0.0305) | 1.20 (0.79–1.82, p = 0.3872) | 0.80 (0.27–2.22, p = 0.6658) |
| Child-Pugh Score | |||
| C/A | 1.69 (1.07–2.65, p = 0.0235) | 0.86 (0.42–1.73, p = 0.6775) | 0.13 (0.01–1.55, p = 0.1068) |
| C/B | 0.93 (0.63–1.35, p = 0.6904) | 0.65 (0.36–1.18, p = 0.1549) | 0.15 (0.01–1.67, p = 0.1234) |
| B/A | 1.83 (1.43–2.33, p < 0.0001) | 1.33 (0.92–1.91, p = 0.1351) | 0.85 (0.30–2.40, p = 0.7584) |
| Main Treatment | |||
| Resection/IO | 0.56 (0.39–0.81, p = 0.0019) | 0.79 (0.42–1.36, p = 0.4118) | 0.39 (0.05–1.92, p = 0.2649) |
| Resection/Systemic | 0.26 (0.16–0.42, p < 0.0001) | 0.29 (0.13–0.64, p = 0.002) | |
| Resection/Supportive | 0.12 (0.08–0.19, p < 0.0001) | 0.12 (0.06–0.25, p < 0.0001) | 0.12 (0.00–5.53, p = 0.2586) |
| IO/Systemic | 0.46 (0.33–0.65, p < 0.0001) | 0.37 (0.21–0.68, p = 0.0017) | |
| IO/Supportive | 0.22 (0.16–0.29, p < 0.0001) | 0.16 (0.10–0.26, p < 0.0001) | 0.31 (0.01–9.82, p = 0.4652) |
| Systemic/Supportive | 0.47 (0.32–0.68, p < 0.0001) | 2.34 (1.23–4.52, p = 0.0093) | |
| Hepatits C Factors | |||
| HCV Infection - yes/no | 0.85 (0.70–1.04, p = 0.1151) | ||
| DAA Therapy - yes/no | 0.39 (0.26–0.58, p < 0.0001) | ||
| SVR12 Attained - yes/no | 0.14 (0.06–0.35, p < 0.0001) | ||
Hazard ratios from multivariable analysis. HR, 95% Confidence Interval, p-value, AJCC: American Joint Committee on Cancer stage, MELD: model for end stage liver disease, IO: interventional oncology, HCV: hepatitis C, DAA: direct-acting antivirals, SVR12: sustained viral response at 12 weeks.